James Paget University Hospitals NHS Foundation Trust
Project Name: James Paget Hospital Nurse Supported Service Development Project Project period: 19 months
Joint working project summary: The James Paget Haematology team at University Hospitals NHS Foundation Trust and Novartis will work in partnership on a joint working project (“JWP”) with the aim to develop: (i) a new Myelofibrosis / Myelodysplastic Syndrome (“MF/MDS”) clinic, led by a consultant and supported by a myeloid nurse; and (ii) the regular assessment of molecular responses for Chronic Myeloid Leukaemia (“CML”) patients by a myeloid nurse, alongside the consultant CML clinics, using the Novartis Treatment Evaluation Polymerase Chain Reaction (“PCR”) Tracker. The NHS team will also develop a new MF/MDS treatment and care protocol, which will include blood transfusion and iron overload treatment, introduce regular health screening for all CML patients on Tyrosine Kinase Inhibitor (“TKI”) therapy and aim to improve patient satisfaction and financial sustainability of the service after the project has completed. A project team will review and measure the impact of this service, with the results included in a JWP summary report and a business case of the new service.
Expected patient outcomes for this project The new MF/MDS clinic, led by a consultant and supported by a myeloid nurse, and the regular assessment of molecular responses for CML patients by the myeloid nurse, aims at:-
improving the treatment of MF/MDS patients with reference to the Anglia and British Committee for Standards in Haematology (“BCSH”) guidelines;
establishing a formal and regular assessment of CML patient molecular responses to optimise CML patient outcomes with reference to the ELN 2013 recommendations;
helping CML patients understand their treatment goals;
improving the quality and consistency of care;
improving patient satisfaction and experience;
improving patient concordance and adherence to therapy.
Start Date & Duration: March 2016 – September 2017